Abstract
In this chapter, evidence from the international literature is collected demonstrating that inducible DAMPs as an own category in the classification, besides DAMPs passively released from necrotic cells, are an integral part of the innate immune system evolved to react in a tailor-made fashion with inflammation-promoting and inflammation-resolving responses. In accordance with their different emission and function, the inducible DAMPs are divided into three classes described in single subchapters entitled (1) native molecules operating as inducible DAMPs, (2) modified molecules acting as inducible DAMPs, and (3) suppressing DAMPs, denoted as inducible “SAMPs.” The most prominent subclasses of native molecules include the cytokines tumor necrosis factor and type I interferons that are actively secreted by DAMP-activated innate immune cells, vascular molecules released from Weibel–Palade bodies, and galectins. Prominent candidates of modified molecules include actively secreted, processed interleukin-1 family members, processed high mobility group box 1, and anaphylatoxins. Subgroups of SAMPs refer to molecules known to contribute not to promotion but to resolution of inflammation. They include prostaglandin E2, cyclic adenosine monophosphate, annexin A1, as well as distinct specialized pro-resolving lipid mediators. Together, the accumulating evidence qualifying inducible DAMPs as molecules involved in inflammation-promoting and inflammation-resolving responses is intriguing in that these functions demonstrate productive activity of the defense system even in scenarios of mild or moderate injury not characterized by the occurrence of cell death. However, in situations in which the damage is severe, secreted inducible DAMPs even cooperate in a tailor-made fashion with DAMPs passively released from necrotic cells, the total outcome being the orchestration of a robust host defense to life-threatening injuries such as caused by viral infections.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Rider P, Voronov E, Dinarello CA, Apte RN, Cohen I. Alarmins: feel the stress. J Immunol. 2017;198
Martin SJ. Cell death and inflammation: the case for IL-1 family cytokines as the canonical DAMPs of the immune system. FEBS J. 2016;283:2599–615. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27273805
Yatim N, Cullen S, Albert ML. Dying cells actively regulate adaptive immune responses. Nat Rev Immunol. 2017;17:262–75. Available from: http://www.nature.com/doifinder/10.1038/nri.2017.9
Daniels M, Brough D. Unconventional pathways of secretion contribute to inflammation. Int J Mol Sci. 2017;18:102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28067797
Bromberg Z, Goloubinoff P, Saidi Y, Weiss YG. The membrane-associated transient receptor potential vanilloid channel is the central heat shock receptor controlling the cellular heat shock response in epithelial cells. PLoS One. 2013;e57149:8. Available from: http://dx.plos.org/10.1371/journal.pone.0057149
Kim Guisbert KS, Guisbert E. SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity. PLoS One. 2017;12:e0176382. Available from: http://dx.plos.org/10.1371/journal.pone.0176382
McMillan DR, Xiao X, Shao L, Graves K, Benjamin IJ. Targeted disruption of heat shock transcription factor 1 abolishes thermotolerance and protection against heat-inducible apoptosis. J Biol Chem. 1998;273:7523–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9516453
Akerfelt M, Morimoto RI, Sistonen L. Heat shock factors: integrators of cell stress, development and lifespan. Nat Rev Mol Cell Biol. 2010;11:545–55. Available from: http://www.nature.com/doifinder/10.1038/nrm2938
Mambula SS, Calderwood SK. Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes. J Immunol. 2006;177:7849–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17114456
Guzhova I, Kislyakova K, Moskaliova O, Fridlanskaya I, Tytell M, Cheetham M, et al. In vitro studies show that Hsp70 can be released by glia and that exogenous Hsp70 can enhance neuronal stress tolerance. Brain Res. 2001;914:66–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11578598
Radons J, Multhoff G. Immunostimulatory functions of membrane-bound and exported heat shock protein 70. Exerc Immunol Rev. 2005;11:17–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16385841
Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 2005;65:5238–47. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-04-3804
Clayton A, Turkes A, Navabi H, Mason MD, Tabi Z. Induction of heat shock proteins in B-cell exosomes. J Cell Sci. 2005;118:3631–8. Available from: http://jcs.biologists.org/cgi/doi/10.1242/jcs.02494
Lancaster GI, Febbraio MA. Exosome-dependent trafficking of HSP70. J Biol Chem. 2005;280:23349–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15826944
Zhan R, Leng X, Liu X, Wang X, Gong J, Yan L, et al. Heat shock protein 70 is secreted from endothelial cells by a non-classical pathway involving exosomes. Biochem Biophys Res Commun. 2009;387:229–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19555663
Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin J-P, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120:457–71. Available from: http://www.jci.org/articles/view/40483
Takeuchi T, Suzuki M, Fujikake N, Popiel HA, Kikuchi H, Futaki S, et al. Intercellular chaperone transmission via exosomes contributes to maintenance of protein homeostasis at the organismal level. Proc Natl Acad Sci U S A. 2015;112:E2497–506. Available from: http://www.pnas.org/lookup/doi/10.1073/pnas.1412651112
Batulan Z, Pulakazhi Venu VK, Li Y, Koumbadinga G, Alvarez-Olmedo DG, Shi C, et al. Extracellular release and signaling by heat shock protein 27: role in modifying vascular inflammation. Front Immunol. 2016;7:285. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27507972
Santos TG, Martins V, Hajj G. Unconventional secretion of heat shock proteins in cancer. Int J Mol Sci. 2017;18:946. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28468249
De Toro J, Herschlik L, Waldner C, Mongini C. Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front Immunol. 2015;6:203. Available from: http://journal.frontiersin.org/Article/10.3389/fimmu.2015.00203/abstract
Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012;31:1062–79. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22252128
Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 2015;6:588. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26635802
Burnstock G, Knight GE. Cell culture: complications due to mechanical release of ATP and activation of purinoceptors. Cell Tissue Res. 2017;370:1–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28434079
Bloy N, Garcia P, Laumont CM, Pitt JM, Sistigu A, Stoll G, et al. Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunol Rev. 2017;280:165–74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29027230
Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011;11:201–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21331080
Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: an overview. Trends Neurosci. 2009;32:19–29. Available from: http://linkinghub.elsevier.com/retrieve/pii/S016622360800249X
Moriyama Y, Hiasa M, Sakamoto S, Omote H, Nomura M. Vesicular nucleotide transporter (VNUT): appearance of an actress on the stage of purinergic signaling. Purinergic Signal. 2017;13:387–404. Available from: http://link.springer.com/10.1007/s11302-017-9568-1
Xia J, Lim JC, Lu W, Beckel JM, Macarak EJ, Laties AM, et al. Neurons respond directly to mechanical deformation with pannexin-mediated ATP release and autostimulation of P2X 7 receptors. J Physiol. 2012;590:2285–304. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22411013
Begandt D, Good ME, Keller AS, DeLalio LJ, Rowley C, Isakson BE, et al. Pannexin channel and connexin hemichannel expression in vascular function and inflammation. BMC Cell Biol. 2017;18:2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28124621
Whyte-Fagundes P, Zoidl G. Mechanisms of pannexin1 channel gating and regulation. Biochim Biophys Acta. 2017;1860(1):65–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28735901
Sohl G, Willecke K. Gap junctions and the connexin protein family. Cardiovasc Res. 2004;62:228–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15094343
Chiu Y-H, Jin X, Medina CB, Leonhardt SA, Kiessling V, Bennett BC, et al. A quantized mechanism for activation of pannexin channels. Nat Commun. 2017;8:14324. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28134257
Qu Y, Misaghi S, Newton K, Gilmour LL, Louie S, Cupp JE, et al. Pannexin-1 is required for ATP release during apoptosis but not for inflammasome activation. J Immunol. 2011;186:6553–61. Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1100478
Ayna G, Krysko DV, Kaczmarek A, Petrovski G, Vandenabeele P, Fésüs L. ATP release from dying autophagic cells and their phagocytosis are crucial for inflammasome activation in macrophages. PLoS One. 2012;7:e40069. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22768222
Robertson J, Lang S, Lambert PA, Martin PE. Peptidoglycan derived from Staphylococcus epidermidis induces Connexin43 hemichannel activity with consequences on the innate immune response in endothelial cells. Biochem J. 2010;432:133–43. Available from: http://biochemj.org/lookup/doi/10.1042/BJ20091753
Garg AD, Agostinis P. ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses. Photochem Photobiol Sci. 2014;13:474–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24493131
Martin S, Dudek-Peric AM, Garg AD, Roose H, Demirsoy S, Van Eygen S, et al. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF V600E inhibitor-resistant metastatic melanoma cells. Autophagy. 2017:1–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28722539
Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkötter C, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43:628–37. Available from: http://doi.wiley.com/10.1002/1529-0131%28200003%2943%3A3%3C628%3A%3AAID-ANR20%3E3.0.CO%3B2-X
Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem. 1997;272:9496–502. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9083090
Tardif MR, Chapeton-Montes JA, Posvandzic A, Pagé N, Gilbert C, Tessier PA. Secretion of S100A8, S100A9, and S100A12 by neutrophils involves reactive oxygen species and potassium efflux. J Immunol Res. 2015;2015:1–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27057553
Murray RZ, Stow JL. Cytokine secretion in macrophages: SNAREs, rabs, and membrane trafficking. Front Immunol. 2014;5:538. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25386181
Adrain C, Zettl M, Christova Y, Taylor N, Freeman M. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science. 2012;335:225–8. Available from: http://www.sciencemag.org/cgi/doi/10.1126/science.1214400
McIlwain DR, Lang PA, Maretzky T, Hamada K, Ohishi K, Maney SK, et al. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science. 2012;335:229–32. Available from: http://www.sciencemag.org/cgi/doi/10.1126/science.1214448
Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651–65. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2011-04-325225
Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants – past, present and future. Cytokine Growth Factor Rev. 2014;25:453–72. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1359610114000781
Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15:362–74. Available from: http://www.nature.com/doifinder/10.1038/nri3834
Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49–62. Available from: http://www.nature.com/doifinder/10.1038/nrrheum.2015.169
Blaser H, Dostert C, Mak TW, Brenner D. TNF and ROS crosstalk in Inflammation. Trends Cell Biol. 2016;26:249–61. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0962892415002494
Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20:1301–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25344738
Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26027717
Shen X-D, Ke B, Ji H, Gao F, Freitas MCS, Chang WW, et al. Disruption of type-I IFN pathway ameliorates preservation damage in mouse orthotopic liver transplantation via HO-1 dependent mechanism. Am J Transplant. 2012;12:1730–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22429450
Trinchieri G. Type I interferon: friend or foe? J Exp Med. 2010;207:2053–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20837696
Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14:36–49. Available from: http://www.nature.com/doifinder/10.1038/nri3581
McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15:87–103. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25614319
Erramilli S, Mannam P, Manthous CA. Influenza SIRS with minimal pneumonitis. Front Med. 2016;3:37. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27630988
Plant EP, Ilyushina NA, Sheikh F, Donnelly RP, Ye Z. Influenza virus NS1 protein mutations at position 171 impact innate interferon responses by respiratory epithelial cells. Virus Res. 2017;240:81–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28757142
Snyder DT, Hedges JF, Jutila MA. Getting “Inside” type I IFNs: type I IFNs in intracellular bacterial infections. J Immunol Res. 2017;2017:1–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28529959
Cohen I, Rider P, Vornov E, Tomas M, Tudor C, Wegner M, et al. Erratum: corrigendum: IL-1α is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity. Sci Rep. 2016;6:19100. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26750721
Rickard JA, O’Donnell JA, Evans JM, Lalaoui N, Poh AR, Rogers T, et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell. 2014;157:1175–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24813849
Martin-Sanchez D, Ruiz-Andres O, Poveda J, Carrasco S, Cannata-Ortiz P, Sanchez-Niño MD, et al. Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI. J Am Soc Nephrol. 2017;28:218–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27352622
Dinarello CA. Interleukin-1 family [IL-1F1, F2]. Cytokine Handb. 2003;2003:643–68.
Fettelschoss A, Kistowska M, LeibundGut-Landmann S, Beer H-D, Johansen P, Senti G, et al. Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proc Natl Acad Sci U S A. 2011;108:18055–60. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.1109176108
Rider P, Kaplanov I, Romzova M, Bernardis L, Braiman A, Voronov E, et al. The transcription of the alarmin cytokine interleukin-1 alpha is controlled by hypoxia inducible factors 1 and 2 alpha in hypoxic cells. Front Immunol. 2012;3:290. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2012.00290/abstract
Rubartelli A, Cozzolino F, Talio M, Sitia R. A novel secretory pathway for interleukin-1 beta, a protein lacking a signal sequence. EMBO J. 1990;9:1503–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2328723
Johnston LK, Bryce PJ. Understanding interleukin 33 and its roles in eosinophil development. Front Med. 2017;4:51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28512632
Balato A, Lembo S, Mattii M, Schiattarella M, Marino R, De Paulis A, et al. IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation. Exp Dermatol. 2012;21:892–4. Available from: http://doi.wiley.com/10.1111/exd.12027
Chen H, Sun Y, Lai L, Wu H, Xiao Y, Ming B, et al. Interleukin-33 is released in spinal cord and suppresses experimental autoimmune encephalomyelitis in mice. Neuroscience. 2015;308:157–68. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0306452215008295
Madouri F, Guillou N, Fauconnier L, Marchiol T, Rouxel N, Chenuet P, et al. Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation. J Mol Cell Biol. 2015;7:351–65. Available from: https://academic.oup.com/jmcb/article-lookup/doi/10.1093/jmcb/mjv012
Lefrançais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard J-P, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A. 2012;109:1673–8. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.1115884109
Blatt AZ, Pathan S, Ferreira VP. Properdin: a tightly regulated critical inflammatory modulator. Immunol Rev. 2016;274:172–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27782331
Ferreira VP, Cortes C, Pangburn MK. Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement. Immunobiology. 2010;215:932–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20382442
Xu W, Berger SP, Trouw LA, de Boer HC, Schlagwein N, Mutsaers C, et al. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. J Immunol. 2008;180:7613–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18490764
Kemper C, Mitchell LM, Zhang L, Hourcade DE. The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis. Proc Natl Acad Sci U S A. 2008;105:9023–8. Available from: http://www.pnas.org/lookup/doi/10.1073/pnas.0801015105
Cortes C, Ohtola JA, Saggu G, Ferreira VP. Local release of properdin in the cellular microenvironment: role in pattern recognition and amplification of the alternative pathway of complement. Front Immunol. 2012;3:412. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2012.00412/abstract
Bongrazio M, Pries AR, Zakrzewicz A. The endothelium as physiological source of properdin: role of wall shear stress. Mol Immunol. 2003;39:669–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12493642
Yasuda K, Vasko R, Hayek P, Ratliff B, Bicer H, Mares J, et al. Functional consequences of inhibiting exocytosis of Weibel-Palade bodies in acute renal ischemia. Am J Physiol Renal Physiol. 2012;302:F713–21. Available from: http://ajprenal.physiology.org/cgi/doi/10.1152/ajprenal.00541.2011
Zhu QM, Yamakuchi M, Lowenstein CJ, Lowenstein CJ. SNAP23 regulates endothelial exocytosis of von willebrand factor. PLoS One. 2015;e0118737:10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26266817
Kuo M-C, Patschan D, Patschan S, Cohen-Gould L, Park H-C, Ni J, et al. Ischemia-induced exocytosis of Weibel-Palade bodies mobilizes stem cells. J Am Soc Nephrol. 2008;19:2321–30. Available from: http://www.jasn.org/cgi/doi/10.1681/ASN.2007111200
Mourik M, Eikenboom J. Lifecycle of Weibel-Palade bodies. Hamostaseologie. 2017;37:13–24. Available from: http://www.schattauer.de/index.php?id=1214&doi=10.5482/HAMO-16-07-0021
Kawecki C, Lenting PJ, Denis CV. von Willebrand factor and inflammation. J Thromb Haemost. 2017;15:1285–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28671350
Michels A, Albánez S, Mewburn J, Nesbitt K, Gould TJ, Liaw PC, et al. Histones link inflammation and thrombosis through the induction of Weibel-Palade Body exocytosis. J Thromb Haemost. 2016.; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27589692
McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res. 2015;107:331–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25994174
Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. Endothelin. Pharmacol Rev. 2016;68:357–418. Available from: http://pharmrev.aspetjournals.org/cgi/doi/10.1124/pr.115.011833
McCormack JJ, Lopes da Silva M, Ferraro F, Patella F, Cutler DF. Weibel−Palade bodies at a glance. J Cell Sci. 2017;130:3611–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29093059
Pendu R, Terraube V, Christophe OD, Gahmberg CG, de Groot PG, Lenting PJ, et al. P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood. 2006;108:3746–52. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2006-03-010322
Zunino B, Rubio-Patiño C, Villa E, Meynet O, Proics E, Cornille A, et al. Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. Oncogene. 2016;35:261–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25867070
Frimat M, Tabarin F, Dimitrov JD, Poitou C, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood. 2013;122:282–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23692858
Stow LR, Jacobs ME, Wingo CS, Cain BD. Endothelin-1 gene regulation. FASEB J. 2011;25:16–28. Available from: http://www.fasebj.org/cgi/doi/10.1096/fj.10-161612
Qin W, Mi S, Li C, Wang G, Zhang J, Wang H, et al. Low shear stress induced HMGB1 translocation and release via PECAM-1/PARP-1 pathway to induce inflammation response. PLoS One. 2015:10, e0120586. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25793984
Liu Y, Yan W, Tohme S, Chen M, Fu Y, Tian D, et al. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol. 2015;63:114–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25681553
Scharfstein J, Schmitz V, Svensjö E, Granato A, Monteiro AC. Kininogens coordinate adaptive immunity through the proteolytic release of bradykinin, an endogenous danger signal driving dendritic cell maturation. Scand J Immunol. 2007;66:128–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17635790
Monteiro AC, Scovino A, Raposo S, Gaze VM, Cruz C, Svensjo E, et al. Kinin Danger signals proteolytically released by gingipain induce fimbriae-specific IFN- and IL-17-producing T cells in mice infected intramucosally with porphyromonas gingivalis. J Immunol. 2009;183:3700–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19687097
Yoshino O, Yamada-Nomoto K, Kobayashi M, Andoh T, Hongo M, Ono Y, et al. Bradykinin system is involved in endometriosis-related pain through endothelin-1 production. Eur J Pain. 2017.; Available from: http://www.ncbi.nlm.nih.gov/pubmed/29034546
Adlbrecht C, Wurm R, Humenberger M, Andreas M, Redwan B, Distelmaier K, et al. Peri-interventional endothelin-A receptor blockade improves long-term outcome in patients with ST-elevation acute myocardial infarction. Thromb Haemost. 2014;112:176–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24695986
Packer M, McMurray JJV, Krum H, Kiowski W, Massie BM, Caspi A, et al. Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure. JACC Hear Fail. 2017;5:317–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28449795
Kuntz M, Leiva-Juarez MM, Luthra S. Systematic review of randomized controlled trials of endothelin receptor antagonists for pulmonary arterial hypertension. Lung. 2016;194:723–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27506903
Yuan W, Cheng G, Li B, Li Y, Lu S, Liu D, et al. Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis. Blood Press. 2017;26:139–49. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27808564
Devuyst O, Olinger E, Rampoldi L. Uromodulin: from physiology to rare and complex kidney disorders. Nat Rev Nephrol. 2017;13:525–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28781372
Anders H-J, Schaefer L. Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. J Am Soc Nephrol. 2014;25:1387–400. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24762401
Säemann MD, Weichhart T, Zeyda M, Staffler G, Schunn M, Stuhlmeier KM, et al. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. J Clin Invest. 2005;115:468–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15650774
Darisipudi MN, Thomasova D, Mulay SR, Brech D, Noessner E, Liapis H, et al. Uromodulin triggers IL-1β-dependent innate immunity via the NLRP3 inflammasome. J Am Soc Nephrol. 2012;23:1783–9. Available from: http://www.jasn.org/cgi/doi/10.1681/ASN.2012040338
Sato S, St-Pierre C, Bhaumik P, Nieminen J. Galectins in innate immunity: dual functions of host soluble beta-galactoside-binding lectins as damage-associated molecular patterns (DAMPs) and as receptors for pathogen-associated molecular patterns (PAMPs). Immunol Rev. 2009;230:172–87. Available from: http://doi.wiley.com/10.1111/j.1600-065X.2009.00790.x
Vasta GR, Feng C, González-Montalbán N, Mancini J, Yang L, Abernathy K, et al. Functions of galectins as “self/non-self”-recognition and effector factors. Pathog Dis. 2017;75:PMID:28449072. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28449072
Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F. Introduction to galectins. Glycoconj J. 2002;19:433–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14758066
Liu F-T, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta. 2002;1572:263–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12223274
Yang R-Y, Rabinovich GA, Liu F-T. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 2008;10:e17. Available from: http://www.journals.cambridge.org/abstract_S1462399408000719
Stewart SE, Menzies SA, Popa SJ, Savinykh N, Petrunkina Harrison A, Lehner PJ, et al. A genome-wide CRISPR screen reconciles the role of N-linked glycosylation in galectin-3 transport to the cell surface. J Cell Sci. 2017;130:3234–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28775154
Ouellet M, St-Pierre C, Tremblay MJ, Sato S. Effect of galectins on viral transmission. Methods Mol Biol. 2015;1207:397–420. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25253155
Sato S, Ouellet M, St-Pierre C, Tremblay MJ. Glycans, galectins, and HIV-1 infection. Ann N Y Acad Sci. 2012;1253:133–48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22524424
Dapat I, Pascapurnama D, Iwasaki H, Labayo H, Chagan-Yasutan H, Egawa S, et al. Secretion of galectin-9 as a DAMP during dengue virus infection in THP-1 cells. Int J Mol Sci. 2017;18:1644. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28788062
Kim B, Lee Y, Kim E, Kwak A, Ryoo S, Bae SH, et al. The interleukin-1α precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front Immunol. 2013;4:391. Available from: http://journal.frontiersin.org/article/10.3389/fimmu.2013.00391/abstract
Alheim K, McDowell TL, Symons JA, Duff GW, Bartfai T. An AP-1 site is involved in the NGF induction of IL-1 alpha in PC12 cells. Neurochem Int. 1996;29:487–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8939459
Mori N, Prager D. Transactivation of the interleukin-1alpha promoter by human T-cell leukemia virus type I and type II Tax proteins. Blood. 1996;87:3410–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8605359
Koo J-H, Yoon H, Kim W-J, Lim S, Park H-J, Choi J-M. Cell membrane penetrating function of the nuclear localization sequence in human cytokine IL-1α. Mol Biol Rep. 2014;41:8117–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25205122
Lange A, Mills RE, Lange CJ, Stewart M, Devine SE, Corbett AH. Classical nuclear localization signals: definition, function, and interaction with importin alpha. J Biol Chem. 2007;282:5101–5. Available from: http://www.jbc.org/lookup/doi/10.1074/jbc.R600026200
Lange A, McLane LM, Mills RE, Devine SE, Corbett AH. Expanding the definition of the classical bipartite nuclear localization signal. Traffic. 2010;11:311–23. Available from: http://doi.wiley.com/10.1111/j.1600-0854.2009.01028.x
Kavita U, Mizel SB. Differential sensitivity of interleukin-1 alpha and -beta precursor proteins to cleavage by calpain, a calcium-dependent protease. J Biol Chem. 1995;270:27758–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7499244
Zheng Y, Humphry M, Maguire JJ, Bennett MR, Clarke MCH. Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1α, controlling necrosis-induced sterile inflammation. Immunity. 2013;38:285–95. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1074761313000484
Kobayashi Y, Yamamoto K, Saido T, Kawasaki H, Oppenheim JJ, Matsushima K. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. Proc Natl Acad Sci U S A. 1990;87:5548–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2115174
Keller M, Rüegg A, Werner S, Beer H-D. Active caspase-1 is a regulator of unconventional protein secretion. Cell. 2008;132:818–31. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0092867408001116
Afonina IS, Tynan GA, Logue SE, Cullen SP, Bots M, Lüthi AU, et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol Cell. 2011;44:265–78. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1097276511007179
Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013;38:209–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23438821
England H, Summersgill HR, Edye ME, Rothwell NJ, Brough D. Release of interleukin-1α or interleukin-1β depends on mechanism of cell death. J Biol Chem. 2014;289:15942–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24790078
Wang L, Wang T, Li H, Liu Q, Zhang Z, Xie W, et al. Receptor interacting protein 3-mediated necroptosis promotes lipopolysaccharide-induced inflammation and acute respiratory distress syndrome in mice. PLoS One. 2016;11:e0155723. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27195494
Zhang L, Wei J, Ren L, Zhang J, Yang M, Jing L, et al. Endosulfan inducing apoptosis and necroptosis through activation RIPK signaling pathway in human umbilical vascular endothelial cells. Environ Sci Pollut Res. 2017;24:215–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27709431
Alam J, Jantan I, Bukhari SNA. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy. Biomed Pharmacother. 2017;92:615–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28582758
Conos SA, Chen KW, De Nardo D, Hara H, Whitehead L, Núñez G, et al. Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner. Proc Natl Acad Sci. 2017;114:E961–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28096356
Sarhan M, Land WG, Tonnus W, Hugo CP, Linkermann A. Origin and consequences of necroinflammation. Physiol Rev. 2018;98(2):727–80.
Land WG. Innate alloimmunity part 2: innate immunity and allograft rejection. Baskent University, Ankara; Pabst Science Publishers, Lengerich. 2011. Available from: ISBN 978-3-89967-738-6.
Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003;22:5551–60. Available from: http://emboj.embopress.org/cgi/doi/10.1093/emboj/cdg516
Lu B, Wang C, Wang M, Li W, Chen F, Tracey KJ, et al. Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review. Expert Rev Clin Immunol. 2014;10:713–27. Available from: http://www.tandfonline.com/doi/full/10.1586/1744666X.2014.909730
Lu B, Wang H, Andersson U, Tracey KJ. Regulation of HMGB1 release by inflammasomes. Protein Cell. 2013;4:163–7. Available from: http://link.springer.com/10.1007/s13238-012-2118-2
Tang Y, Zhao X, Antoine D, Xiao X, Wang H, Andersson U, et al. Regulation of posttranslational modifications of HMGB1 during immune responses. Antioxid Redox Signal. 2016;24:620–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26715031
Hao N, Budnik BA, Gunawardena J, O’Shea EK. Tunable signal processing through modular control of transcription factor translocation. Science. 2013;339:460–4. Available from: http://www.sciencemag.org/cgi/doi/10.1126/science.1227299
Lu B, Antoine DJ, Kwan K, Lundbäck P, Wähämaa H, Schierbeck H, et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A. 2014;111:3068–73. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.1316925111
Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc Natl Acad Sci U S A. 2004;101:9745–50. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.0308558101
Griffiths GM. Secretion from myeloid cells: secretory lysosomes. Microbiol Spectr. 2016;4:PMID:27726815. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27726815
Marim FM, Franco MMC, Gomes MTR, Miraglia MC, Giambartolomei GH, Oliveira SC. The role of NLRP3 and AIM2 in inflammasome activation during Brucella abortus infection. Semin Immunopathol. 2017;39:215–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27405866
Vénéreau E, Ceriotti C, Bianchi ME. DAMPs from cell death to new life. Front Immunol. 2015;6:422. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26347745
Thapa RJ, Ingram JP, Ragan KB, Nogusa S, Boyd DF, Benitez AA, et al. DAI senses influenza A virus genomic RNA and activates RIPK3-dependent cell death. Cell Host Microbe. 2016;20:674–81. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1931312816303924
Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21219181
Blériot C, Lecuit M. The interplay between regulated necrosis and bacterial infection. Cell Mol Life Sci. 2016;73:2369–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27048818
Qiang X, Yang W-L, Wu R, Zhou M, Jacob A, Dong W, et al. Cold-inducible RNA-binding protein (CIRP) triggers inflammatory responses in hemorrhagic shock and sepsis. Nat Med. 2013;19:1489–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24097189
Roumenina L. Personal communication.
Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I – molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26082779
Schatz-Jakobsen JA, Yatime L, Larsen C, Petersen SV, Klos A, Andersen GR. Structural and functional characterization of human and murine C5a anaphylatoxins. Acta Crystallogr Sect D Biol Crystallogr. 2014;70:1704–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24914981
Verschoor A, Karsten CM, Broadley SP, Laumonnier Y, Köhl J. Old dogs-new tricks: immunoregulatory properties of C3 and C5 cleavage fragments. Immunol Rev. 2016;274:112–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27782330
Bajic G, Degn SE, Thiel S, Andersen GR. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO J. 2015;34:2735–57. Available from: http://emboj.embopress.org/cgi/doi/10.15252/embj.201591881
Kolev M, Le Friec G, Kemper C. Complement—tapping into new sites and effector systems. Nat Rev Immunol. 2014;14:811–20. Available from: http://www.nature.com/doifinder/10.1038/nri3761
Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015;6:257. Available from: http://www.frontiersin.org/Molecular_Innate_Immunity/10.3389/fimmu.2015.00257/abstract
Potempa M, Potempa J. Protease-dependent mechanisms of complement evasion by bacterial pathogens. Biol Chem. 2012;393:873–88. Available from: https://www.degruyter.com/view/j/bchm.2012.393.issue-9/hsz-2012-0174/hsz-2012-0174.xml
Klos A, Wende E, Wareham KJ, Monk PN. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev. 2013;65:500–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23383423
Klos A, Tenner AJ, Johswich K-O, Ager RR, Reis ES, Köhl J. The role of the anaphylatoxins in health and disease. Mol Immunol. 2009;46:2753–66. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0161589009001965
Ricklin D, Lambris JD. New milestones ahead in complement-targeted therapy. Semin Immunol. 2016;28:208–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27321574
Wong EKS, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res. 2015;165:306–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25468487
Jore MM, Johnson S, Sheppard D, Barber NM, Li YI, Nunn MA, et al. Structural basis for therapeutic inhibition of complement C5. Nat Struct Mol Biol. 2016;23:378–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27018802
Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, et al. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol. 2017;187:304–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27784126
Heneka MT. Microglial demise and the progression of Alzheimer’s diseases. Cell death immune disorder. Leuven: European Conference; 2017.
Cai X, Xu H, Chen ZJ. Prion-like polymerization in immunity and inflammation. Cold Spring Harb Perspect Biol. 2017;9:a023580. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27881448
Bratton DL, Henson PM. Neutrophil clearance: when the party is over, clean-up begins. Trends Immunol. 2011;32:350–7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1471490611000779
O’Callaghan G, Houston A. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol. 2015;172:5239–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26377664
Kawahara K, Hohjoh H, Inazumi T, Tsuchiya S, Sugimoto Y. Prostaglandin E2-induced inflammation: relevance of prostaglandin E receptors. Biochim Biophys Acta Mol Cell Biol Lipids. 2015;1851:414–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25038274
Hangai S, Ao T, Kimura Y, Matsuki K, Kawamura T, Negishi H, et al. PGE2 induced in and released by dying cells functions as an inhibitory DAMP. Proc Natl Acad Sci U S A. 2016;113:3844–9. Available from: http://www.pnas.org/lookup/doi/10.1073/pnas.1602023113
Koga K, Takaesu G, Yoshida R, Nakaya M, Kobayashi T, Kinjyo I, et al. Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity. 2009;30:372–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19285436
Sokolowska M, Chen L-Y, Liu Y, Martinez-Anton A, Qi H-Y, Logun C, et al. Prostaglandin E2 inhibits NLRP3 inflammasome activation through EP4 receptor and intracellular cyclic AMP in human macrophages. J Immunol. 2015;194:5472–87. Available from: http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1401343
Lima KM, Vago JP, Caux TR, Negreiros-Lima GL, Sugimoto MA, Tavares LP, et al. The resolution of acute Inflammation induced by cyclic AMP is dependent on annexin A1. J Biol Chem. 2017;292(33):13758–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28655761
Perretti M, D’Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol. 2009;9:62–70. Available from: http://www.nature.com/doifinder/10.1038/nri2470
Gavins FNE, Hickey MJ. Annexin A1 and the regulation of innate and adaptive immunity. Front Immunol. 2012;3:354. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23230437
Sousa LP, Alessandri AL, Pinho V, Teixeira MM. Pharmacological strategies to resolve acute inflammation. Curr Opin Pharmacol. 2013;13:625–31. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1471489213000416
Sugimoto MA, Vago JP, Teixeira MM, Sousa LP. Annexin A1 and the resolution of inflammation: modulation of neutrophil recruitment, apoptosis, and clearance. J Immunol Res. 2016;2016:1–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26885535
Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510:92–101. Available from: http://www.nature.com/doifinder/10.1038/nature13479
Basil MC, Levy BD. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat Rev Immunol. 2015;16:51–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26688348
Serhan CN, Chiang N, Dalli J, Levy BD. Lipid mediators in the resolution of inflammation. Cold Spring Harb Perspect Biol. 2014;7:a016311. Available from: http://cshperspectives.cshlp.org/lookup/doi/10.1101/cshperspect.a016311
Anderson HA, Maylock CA, Williams JA, Paweletz CP, Shu H, Shacter E. Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol. 2003;4:87–91. Available from: http://www.nature.com/doifinder/10.1038/ni871
Frasch SC, Bratton DL. Emerging roles for lysophosphatidylserine in resolution of inflammation. Prog Lipid Res. 2012;51:199–207. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22465125
Frasch SC, Fernandez-Boyanapalli RF, Berry KAZ, Murphy RC, Leslie CC, Nick JA, et al. Neutrophils regulate tissue neutrophilia in inflammation via the oxidant-modified lipid lysophosphatidylserine. J Biol Chem. 2013;288:4583–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23293064
Zagórska A, Través PG, Lew ED, Dransfield I, Lemke G. Diversification of TAM receptor tyrosine kinase function. Nat Immunol. 2014;15:920–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25194421
Franz S, Muñoz LE, Heyder P, Herrmann M, Schiller M. Unconventional apoptosis of polymorphonuclear neutrophils (PMN): staurosporine delays exposure of phosphatidylserine and prevents phagocytosis by MΦ-2 macrophages of PMN. Clin Exp Immunol. 2015;179:75–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24995908
Griffiths HR, Gao D, Pararasa C. Redox regulation in metabolic programming and inflammation. Redox Biol. 2017;12:50–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28212523
Lemke G. Phosphatidylserine is the signal for TAM receptors and their ligands. Trends Biochem Sci. 2017;42:738–48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28734578
Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol. 2002;23:144–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11864843
Rodríguez M, Domingo E, Municio C, Alvarez Y, Hugo E, Fernández N, et al. Polarization of the innate immune response by prostaglandin E2: a puzzle of receptors and signals. Mol Pharmacol. 2014;85:187–97. Available from: http://molpharm.aspetjournals.org/cgi/doi/10.1124/mol.113.089573
Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10:181–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20168319
Sousa LP, Lopes F, Silva DM, Tavares LP, Vieira AT, Rezende BM, et al. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaB-independent manner. J Leukoc Biol. 2010;87:895–904. Available from: http://www.jleukbio.org/cgi/doi/10.1189/jlb.0809540
Yan K, Gao L-N, Cui Y-L, Zhang Y, Zhou X. The cyclic AMP signaling pathway: exploring targets for successful drug discovery (review). Mol Med Rep. 2016;13:3715–23. Available from: https://www.spandidos-publications.com/
Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of inflammation: what controls its onset? Front Immunol. 2016;7:160. Available from: http://journal.frontiersin.org/Article/10.3389/fimmu.2016.00160/abstract
Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, et al. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev. 2009;61:119–61. Available from: http://pharmrev.aspetjournals.org/cgi/doi/10.1124/pr.109.001578
Li Y, Cai L, Wang H, Wu P, Gu W, Chen Y, et al. Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. Oncogene. 2011;30:3887–99. Available from: http://www.nature.com/doifinder/10.1038/onc.2011.112
Perucci LO, Sugimoto MA, Gomes KB, Dusse LM, Teixeira MM, Sousa LP. Annexin A1 and specialized proresolving lipid mediators: promoting resolution as a therapeutic strategy in human inflammatory diseases. Expert Opin Ther Targets. 2017;21:879–96. Available from: https://www.tandfonline.com/doi/full/10.1080/14728222.2017.1364363
Pupjalis D, Goetsch J, Kottas DJ, Gerke V, Rescher U. Annexin A1 released from apoptotic cells acts through formyl peptide receptors to dampen inflammatory monocyte activation via JAK/STAT/SOCS signalling. EMBO Mol Med. 2011;3:102–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21254404
Weyd H, Abeler-Dörner L, Linke B, Mahr A, Jahndel V, Pfrang S, et al. Annexin A1 on the surface of early apoptotic cells suppresses CD8+ T cell immunity. PLoS One. 2013;e62449:8. Available from: http://dx.plos.org/10.1371/journal.pone.0062449
Kasuga K, Yang R, Porter TF, Agrawal N, Petasis NA, Irimia D, et al. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol. 2008;181:8677–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19050288
Dalli J, Serhan C. Macrophage proresolving mediators-the when and where. Microbiol Spectr. 2016;4 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27337457
Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol. 2008;8:327–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18421305
Lemke G. Biology of the TAM receptors. Cold Spring Harb Perspect Biol. 2013;5:a009076. Available from: http://cshperspectives.cshlp.org/lookup/doi/10.1101/cshperspect.a009076
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Land, W.G. (2018). Endogenous DAMPs, Category III: Inducible DAMPs (Cat. III DAMPs). In: Damage-Associated Molecular Patterns in Human Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-78655-1_14
Download citation
DOI: https://doi.org/10.1007/978-3-319-78655-1_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-78654-4
Online ISBN: 978-3-319-78655-1
eBook Packages: MedicineMedicine (R0)